Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-10-29

DOI:

10.1016/s1470-2045(25)00475-9

Affiliations:

23

Authors:

25

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	4.043478	0.16
Chris O'Brien Lifehouse, Australia	1.043478	0.04
Fudan University Shanghai Cancer Center (FUSCC), China	1.043478	0.04
University of Vermont (UVM), United States of America (USA)	1.043478	0.04
Sakura Medical Center, Toho University, Japan	1.043478	0.04
Yokohama City University Medical Center, YCU, Japan	1.043478	0.04
University College Hospital (UCH), United Kingdom (UK)	1.043478	0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.043478	0.04
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)	1.043478	0.04
Associated Medical Professionals, United States of America (USA)	1.043478	0.04
Ovidius University of Constanta, Romania	1.043478	0.04
Studienpraxis Urologie, Germany	1.043478	0.04
Gregorio Marañon University Hospital, Spain	1.043478	0.04
Centre Léon Bérard (CLB), France	1.043478	0.04
Asan Medical Center (AMC), South Korea	1.043478	0.04
University of California, San Diego (UC San Diego), United States of America (USA)	1.043478	0.04
Massachusetts General Hospital (MGH), United States of America (USA)	1.043478	0.04
Bellvitge Biomedical Research Institute (IDIBELL), Spain	1.043478	0.04
Hospital Universitario Ramón y Cajal, Spain	1.043478	0.04
Peter MacCallum Cancer Centre (Peter Mac), Australia	0.543478	0.02
The University of Melbourne (UniMelb), Australia	0.543478	0.02
Hunan Cancer Hospital, China	0.543478	0.02
Xiangya School of Medicine, CSU, China	0.543478	0.02

Interested in Oncology and Carcinogenesis?